Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jiří Tomášek"'
Autor:
J. Han van Krieken, George Kafatos, James Bennett, Laurent Mineur, Jiří Tomášek, Etienne Rouleau, Pavel Fabian, Giovanna De Maglio, Pilar García-Alfonso, Giuseppe Aprile, Parijan Parkar, Gerald Downey, Gaston Demonty, Jörg Trojan
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background In Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies – a physician survey and a medical records review (MRR) – were conducted to
Externí odkaz:
https://doaj.org/article/18d47edf49e44600a880412a7960bfe2
Autor:
Jörg Trojan, Laurent Mineur, Jiří Tomášek, Etienne Rouleau, Pavel Fabian, Giovanna de Maglio, Pilar García-Alfonso, Giuseppe Aprile, Aliki Taylor, George Kafatos, Gerald Downey, Jan-Henrik Terwey, J Han van Krieken
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140717 (2015)
From 2008-2013, the European indication for panitumumab required that patients' tumor KRAS exon 2 mutation status was known prior to starting treatment. To evaluate physician awareness of panitumumab prescribing information and how physicians prescri
Externí odkaz:
https://doaj.org/article/83be4ab33e8b42c49b31ebf3e234d3d3
Autor:
Jiří Tomášek
Publikováno v:
Medicína pro praxi. 16:186-189
Ceska republika je celosvětově na spici žebřicku incidence kolorektalniho karcinomu. Každý rok je v CR zhoubný nador tlusteho střeva zjistěn asi u 5 500 osob, karcinom konecniku je nově diagnostikovan u 2 500 pacientů. Casna stadia onemocn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29d1070c193a7f61ea6501c9eb281994
https://doi.org/10.36290/med.2019.026
https://doi.org/10.36290/med.2019.026
Autor:
Arndt Vogel, Christophe Borg, Vincenzo Dadduzio, Reigetsu Yoshikawa, Eric Assenat, Giovanni Brandi, Min-Hua Jen, Kenta Shinozaki, Marc Pracht, Kenta Motomura, Masatoshi Kudo, Philippe Merle, Takuji Okusaka, Jiří Tomášek, Nora Drove Ubreva, Ryan C. Widau, Richard S. Finn, Bruno Daniele, Manabu Morimoto, Andrew X. Zhu, Josep M. Llovet, Peter R. Galle
Publikováno v:
Liver International
Liver International, Wiley-Blackwell, 2020, 40 (8), pp.2008-2020. ⟨10.1111/liv.14462⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Liver International, Wiley-Blackwell, 2020, 40 (8), pp.2008-2020. ⟨10.1111/liv.14462⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Background & Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04eaf2e95d78f31887f70a02125cabd9
https://pubmed.ncbi.nlm.nih.gov/32279446
https://pubmed.ncbi.nlm.nih.gov/32279446
Autor:
George Kafatos, J. Han van Krieken, Parijan Parkar, Jörg Trojan, Etienne Rouleau, Gerald Downey, Giuseppe Aprile, Laurent Mineur, Pilar García-Alfonso, Jiří Tomášek, Pavel Fabian, Giovanna De Maglio, James Bennett, Gaston Demonty
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
BMC Cancer
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
BMC Cancer
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background In Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies – a physician survey and a medical records review (MRR) – were conducted to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::939351c5261be1362ca13dd0750070e5
http://link.springer.com/article/10.1186/s12885-017-3740-4
http://link.springer.com/article/10.1186/s12885-017-3740-4
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 32(5)
Stage IV colorectal cancer is associated with high mortality, and the prognosis is significantly worse for patients have peritoneal metastases. Peritoneal carcinomatosis from colorectal cancer was considered incurable with an infaust prognosis. Media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b47e163944ea7fcce6472ae9d22ddba7
https://pubmed.ncbi.nlm.nih.gov/31610665
https://pubmed.ncbi.nlm.nih.gov/31610665
Autor:
Petr Dytrych, Jiří Tomášek, Libor Nemec, Dušan Klos, František Antoš, Miroslav Levý, David Hoskovec, Petr Bartoška
Publikováno v:
Klinicka Onkologie. 32
This article provides an introduction to peritoneal tumors, which are the subject of a series of review papers published in Issue 5 (2019) of Klinicka onkologie. Many malignant peritoneal tumors are characterized by production of mucinous and gelatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c72355740a1440a011b17252fa93eb8c
https://doi.org/10.14735/amko2019324
https://doi.org/10.14735/amko2019324
Autor:
J. Han Van Krieken, Kafatos, George, Bennett, James, Mineur, Laurent, Jiří Tomášek, Rouleau, Etienne, Fabian, Pavel, Maglio, Giovanna De, García-Alfonso, Pilar, Aprile, Giuseppe, Parijan Parkar, Downey, Gerald, Demonty, Gaston, Trojan, Jörg
Interview guide/questionnaire used for the telephone interviews. (DOCX 61 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca5d680d7bdb5886609857bcb3d37ab
Autor:
J. Han Van Krieken, Kafatos, George, Bennett, James, Mineur, Laurent, Jiří Tomášek, Rouleau, Etienne, Fabian, Pavel, Maglio, Giovanna De, García-Alfonso, Pilar, Aprile, Giuseppe, Parijan Parkar, Downey, Gerald, Demonty, Gaston, Trojan, Jörg
List of all Ethical committees that approved the study. (DOCX 16 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04aeda56f4c5a221fe3ef3b2c8c8f45c
Autor:
M-H. Jen, Manabu Morimoto, Richard S. Finn, Gosuke Homma, Bruno Daniele, Kenta Shinozaki, Takuji Okusaka, Marc Pracht, Kenta Motomura, Philippe Merle, Josep M. Llovet, Eric Assenat, Peter R. Galle, Andrew X. Zhu, Jiří Tomášek, Masatoshi Kudo, Giovanni Brandi, Vittorina Zagonel, Christophe Borg, Reigetsu Yoshikawa
Publikováno v:
Annals of Oncology. 30:v292
Background REACH (NCT01140347) and REACH-2 (NCT02435433) were two global, randomized, double-blind, placebo (PL)-controlled multicenter, phase 3 studies of RAM vs PL in patients with HCC after prior sorafenib. REACH-2 confirmed overall survival (OS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11b31b1a5fafdc54cd3aa685dd702e6c
https://doi.org/10.1093/annonc/mdz247.083
https://doi.org/10.1093/annonc/mdz247.083